Innate Pharma reports €96.8M in cash, outlines key 2027 pipeline milestones (IPHA:NASDAQ)
Innate Pharma reported 9M revenue of €3.4M, up from €2.3M a year ago. The company had €96.8M in cash at September 30, 2026, including funds from a Sobi transaction and private placement. It outlined key 2027 pipeline milestones.
How this was made
The 30-second read
Why it matters
The cash update provides a baseline for liquidity assessment ahead of upcoming trial readouts.
Market read
A modest cash position update with limited immediate trading impact.
What to watch
Potential upcoming partnership or grant not disclosed could change the outlook.
Background
Innate Pharma is a clinical‑stage immuno‑oncology company listed on NASDAQ under IPHA.
Ticker impact
Press release discloses €96.8M cash and €3.4M revenue for Q3 2026, new financial figures for the company.
potential modest pressure as market prices in limited cash position
The disclosed cash amount is modest for a biotech; no major catalyst beyond the update, so price move likely limited.
Market effects
Minor signal for European biotech cash‑burn trends.
Limited impact on broader European markets.
Low relevance globally.
Counterpoint
Investors could see the cash balance as a floor supporting future R&D spend.
Key entities
- companyInnate Pharma
Biotech firm reporting cash and revenue figures.
